Jazz Pharmaceuticals PLC $JAZZ Stake Lowered by Grantham Mayo Van Otterloo & Co. LLC

Grantham Mayo Van Otterloo & Co. LLC decreased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 72.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 2,267 shares of the specialty pharmaceutical company’s stock after selling 5,854 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Jazz Pharmaceuticals were worth $241,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JAZZ. SVB Wealth LLC bought a new position in Jazz Pharmaceuticals during the 1st quarter worth $36,000. Hantz Financial Services Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the last quarter. Brooklyn Investment Group grew its position in shares of Jazz Pharmaceuticals by 411.1% during the first quarter. Brooklyn Investment Group now owns 552 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 444 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $80,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 3.1%

JAZZ opened at $166.71 on Wednesday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The company has a market capitalization of $10.13 billion, a PE ratio of -24.77, a P/E/G ratio of 8.49 and a beta of 0.30. The stock’s fifty day moving average is $145.46 and its 200-day moving average is $126.14. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99.

Analysts Set New Price Targets

JAZZ has been the subject of several recent analyst reports. Truist Financial upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Wells Fargo & Company increased their price objective on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, November 26th. Royal Bank Of Canada set a $194.00 price target on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday, November 17th. Finally, The Goldman Sachs Group raised their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $195.67.

Insider Buying and Selling

In related news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total value of $13,780,275.00. Following the sale, the director directly owned 393,332 shares in the company, valued at $69,938,362.92. The trade was a 16.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Heather Ann Mcsharry sold 3,415 shares of the company’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $177.78, for a total value of $607,118.70. Following the completion of the transaction, the director directly owned 20,449 shares in the company, valued at $3,635,423.22. This represents a 14.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 122,393 shares of company stock worth $21,568,254 in the last ninety days. Insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.